New immunotherapy before surgery for multiple cancer types
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests new immunotherapy combinations given before surgery for cancers that have certain genetic features (dMMR or pMMR). It aims to see if these drugs can shrink tumors and improve outcomes for patients with various cancer types, including those for which standard neoadjuvant therapy is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a newly diagnosed cancer that is either dMMR or pMMR and is one of the types listed (like sarcoma, head and neck, anal, or esophageal cancer) or in another group.
- Your cancer has not spread to other parts of the body (non-metastatic).
- You are healthy enough for daily activities (WHO performance status 0 or 1).
- You have adequate blood counts and organ function as shown by recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This trial tests two new immunotherapy drugs (botensilimab and balstilimab) given after standard treatment for stage II or III colorectal cancer. The drugs are designed to boost your immune system to prevent cancer from coming back, especially if cancer cells are detected in your blood.
This trial tests pembrolizumab (an immunotherapy medicine) given before curative surgery in people with certain MMR-deficient colon or rectal cancers. It aims to shrink or control the cancer so surgery can be done more effectively, and to see if outcomes improve compared with standard care.
This trial tests two immunotherapy drugs, zanzalintinib and retifanlimab, given before surgery to remove colon cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes for people with a specific type of colon cancer (called pMMR/MSS).
Hear when a new Resectable MMR-deficient Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.